Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

Anti-Cancer Drugs

Volumn 12, Issue 4, 2001, Pages 315-323

  Meerum Terwogt, Jetske M ^a,b   Ten Bokkel Huinink, Wim W ^a   Schellens, Jan H M ^a,d   Schot, Margaret ^a   Mandjes, Ingrid A M ^a   Zurlo, Maria G ^c   Rocchetti, Marurizio ^c   Rosing, Hilde ^b   Koopman, Franciska J ^b   Beljnen, Jos H ^a,b,d  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c PFIZER INC   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

HPMA copolymers; Paclitaxel; Pharmacokinetics; Phase 1 study; PNU166945; Polymeric drug conjugates

Indexed keywords

PACLITAXEL DERIVATIVE; PNU 166945; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LUNG CANCER; MALE; MUCOSA INFLAMMATION; MYALGIA; NEUROTOXICITY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANEMIA; AREA UNDER CURVE; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; METHACRYLATES; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OVARIAN NEOPLASMS; PACLITAXEL; POLYMERS; PRODRUGS; REMISSION INDUCTION; SKIN NEOPLASMS; SOLUBILITY; TAXOIDS;

EID: 0035012701     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200104000-00003     Document Type: Article

References (28)

1. 1. Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2117-35.
2. 2. Huizing MT, Sewberath Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404.
3. 3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel in patients with stage III and stage IV ovarian cancer. New Engl J Med 1996; 334: 1-6.
4. 4. Huizing MT, Giaccone G, van Warmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997; 15: 317-29.
5. 5. Rowinsky EK, Donehower RC. Paclitaxel (taxol). New Engl J Med 1995; 332: 1004-14.
6. 6. Nannan Panday VR, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 1997 14: 418-27.
7. 7. Lorenz W, Reimann HJ, Schmall A, et al. Histamine release in days by Cremophor EL and its derivatives. Ag Actions 1977; 7: 63-7.
8. 8. Dorr RT. Pharmacology and toxicology of cremophor EL diluent. Ann Pharmacother 1994; 28: S11-4.
9. 9. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19: 458-77.
10. 10. Pesenti E, Franzetti C, Ciomei M, et al. Synthesis and biological activity of water soluble polymer-bound taxol derivatives. Proc Am Ass Cancer Res 1995; 36: 307.
11. 11. Pharmacia & Upjohn. Investigator's brochure FCE 28161, copy no. 001, June 1996.
12. 12. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 1992; 3: 175-210.
13. 13. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute 1988.
14. 14. Meerum Terwogt JM, Rosing H, Rochetti M, et al. High-performance liquid chromatographic methods for the determination of a novel polymer-bound paclitaxel derivative (PNU166945) and free paclitaxel in human plasma. J Liq Chromatogr Rel Technol 2000; 23: 1233-51.
15. 15. Gibaldi M, Perrier D, Noncompartmental analysis based on statistical moment theory, In: Swarbrick J, ed. Pharmacokinetics. New York, NY: Marcel Dekker 1982: 409-17.
16. 16. Kopecek J, Bazilova H. Poly[N-(2-hydroxypropyl)methacrylamide] 1. Radical polymerisation and copolymerisation. Eur Polym J 1973; 9: 7-14.
17. 17. Sprincl L, Exner J, Sterba O, Kopecek J. New types of synthetic infusion solutions III. Elimination and retention of poly[N(2-hydroxypropyl)methacrylamide] in a test organism. J Biomed Mater Res 1976; 10: 953-6.
18. 18. Kopecek J, Rihova B, Krinick N. Targetable photoactiva-table polymeric drugs. J Control Rel 1991; 16: 137-44.
19. 19. Peterson CM, Lu JM, Sun Y, et al. Combination chemotherapy and photodynamic therapy with N(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res 1996; 56: 3980-5.
20. 123I-labelled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J Drug Target 1996; 3: 385-90.
21. 123I-labelled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugates in mice with transplated melanoma and mammary carcinoma. J Drug Target 1996; 3: 375-83.
22. 22. Vasey PA, Twelves C, Kaye SB, et al. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Presented at the 3rd Int Symp On Polymer Therapeutics, London 7-9 January 1998.
23. 23. Kerr DJ, Seymour LW, Boivin C, et al. Phase I and clinical trial of HPMA copolymers bearing doxorubicin and galactosamine. Presented at the 3rd Int Symp on Polymer Therapeutics, London 7-9 January 1998.
24. 24. Nannan Panday VR, Meerum Terwogt JM, ten Bokkel Huinink WW, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble prodrug of paclitaxel. Proc Am Soc Clin Oncol 1998; 17: 742.
25. 25. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase Ii study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 478-84.
26. 26. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996; 56: 2112-5.
27. 27. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90.
28. 28. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Center (ECC) trial. Ann Oncol 1995; 6: 699-704.